Publications

Prevalence of TB and health-seeking behaviour.

Abstract

No abstract available

Conan N Simons E Ohler L Mbatha M van Cutsem G Huerga H
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2022 May 01; 26(5); . doi: 10.5588/ijtld.22.0001. Epub 2022 05 05

SARS-CoV-2 Antibody Prevalence and Population-Based Death Rates, Greater Omdurman, Sudan.

Abstract

In a cross-sectional survey in Omdurman, Sudan, during March-April 2021, we estimated that 54.6% of the population had detectable severe acute respiratory syndrome coronavirus 2 antibodies.

Moser W Fahal MAH Abualas E Bedri S Elsir MT Mohamed MFERO Mahmoud AB Ahmad AII Adam MA Altalib S DafaAllah OA Hmed SA Azman AS Ciglenecki I Gignoux E González A Mwongera C Miranda MA
Emerging infectious diseases 2022 May ; 28(5); . doi: 10.3201/eid2805.211951. Epub 2022 04 25
Abualas E Bedri S COVID-19 Elsir MT Fahal MAH Mohamed MFERO Omdurman SARS-CoV-2 Sudan Sudan. Emerg Infect Dis. 2022 May [date cited]. https://doi.org/10.3201/eid2805.211951 Suggested citation for this article: Moser W antibody et al. SARS-CoV-2 antibody prevalence and population-based death rates excess mortality greater Omdurman respiratory infections seroprevalence severe acute respiratory syndrome coronavirus 2 viruses zoonoses

Feasibility and acceptability of using the novel urine-based FujiLAM test to detect tuberculosis: A multi-country mixed-methods study.

Abstract

Background: The novel urine-based FujiLAM test identifies tuberculosis in HIV-positive patients but may be challenging to use at point-of-care (POC).

Chenai Mathabire Rücker S Lissouba P Akinyi M Vicent Lubega A Stewart R Tamayo Antabak N Taremwa Mugisha I Ohler L Macuácua H Atieno M Muyindike W Turyahabwe S Odhiambo Okomo G Mahomed Couto A Musoke M Bossard C Hewison C Ndlovu Z Huerga H
Journal of clinical tuberculosis and other mycobacterial diseases 2022 May ; 27; . doi: 10.1016/j.jctube.2022.100316. Epub 2022 04 25
Diagnostic tests Feasibility studies FujiLAM Low income settings Tuberculosis

Evaluation of multiple micronutrient supplementation and medium-quantity lipid-based nutrient supplementation in pregnancy on child development in rural Niger: A secondary analysis of a cluster randomized controlled trial.

Abstract

BACKGROUND: It is estimated that over 250 million children under 5 years of age in low- and middle-income countries (LMICs) do not reach their full developmental potential.

Sudfeld CR Bliznashka L Salifou A Guindo O Soumana I Adehossi I Langendorf C Grais RF Isanaka S
PLoS medicine 2022 May ; 19(5); . doi: 10.1371/journal.pmed.1003984. Epub 2022 05 02

The seasonality of cholera in sub-Saharan Africa: a statistical modelling study.

Abstract

BACKGROUND: Cholera remains a major threat in sub-Saharan Africa (SSA), where some of the highest case-fatality rates are reported.

Perez-Saez J Lessler J Lee EC Luquero FJ Malembaka EB Finger F Langa JP Yennan S Zaitchik B Azman AS
The Lancet. Global health 2022 Apr 21; . doi: 10.1016/S2214-109X(22)00007-9. Epub 2022 04 21

Risk of community- and hospital-acquired bacteremia and profile of antibiotic resistance in children hospitalized with severe acute malnutrition in Niger.

Abstract

OBJECTIVE: To estimate the prevalence and antibiotic resistance profile of community- and hospital-acquired bacteremia among hospitalized children with severe acute malnutrition in Niger.

Andersen CT Langendorf C Garba S Sayinzonga-Makombe N Mambula C Mouniaman I Hanson KE Grais RF Isanaka S
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2022 Mar 25; . doi: 10.1016/j.ijid.2022.03.047. Epub 2022 03 25
Niger antimicrobial resistance bacteremia community-acquired hospital-acquired nosocomial severe acute malnutrition

Tuberculosis screening among HIV-positive inpatients: a systematic review and individual participant data meta-analysis.

Abstract

BACKGROUND: Since 2011, WHO has recommended that HIV-positive inpatients be routinely screened for tuberculosis with the WHO four-symptom screen (W4SS) and, if screened positive, receive a molecular WHO-recommended rapid diagnostic tes

Dhana A Hamada Y Kengne AP Kerkhoff AD Rangaka MX Kredo T Baddeley A Miller C Gupta-Wright A Fielding K Wood R Huerga H Rücker SCM Heidebrecht C Wilson D Bjerrum S Johansen IS Thit SS Kyi MM Hanson J Barr DA Meintjes G Maartens G
The lancet. HIV 2022 Mar 17; . doi: 10.1016/S2352-3018(22)00002-9. Epub 2022 03 17

Protocol for a phase 3 trial to evaluate the effectiveness and safety of a heterologous, two-dose vaccine for Ebola virus disease in the Democratic Republic of the Congo.

Abstract

INTRODUCTION: Ebola virus disease (EVD) continues to be a significant public health problem in sub-Saharan Africa, especially in the Democratic Republic of the Congo (DRC).

Watson-Jones D Kavunga-Membo H Grais RF Ahuka S Roberts N Edmunds WJ Choi EM Roberts CH Edwards T Camacho A Lees S Leyssen M Spiessens B Luhn K Douoguih M Hatchett R Bausch DG Muyembe JJ
BMJ open 2022 03 08; 12(3); . doi: 10.1136/bmjopen-2021-055596. Epub 2022 03 08
Ebola infectious diseases public health tropical medicine vaccine

Safety and effectiveness outcomes from a 14-country cohort of patients with multi-drug resistant tuberculosis treated concomitantly with bedaquiline, delamanid and other second-line drugs.

Abstract

BACKGROUND: Concomitant use of bedaquiline (Bdq) and delamanid (Dlm) for multi-drug/rifampicin resistant tuberculosis (MDR/RR-TB) has raised concerns about a potentially poor risk-benefit ratio.

Huerga H Khan U Bastard M Mitnick CD Lachenal N Khan PY Seung KJ Melikyan N Ahmed S Rich ML Varaine F Osso E Rashitov M Salahuddin N Salia G Sánchez E Serobyan A Siddiqui MR Tefera DG Vetushko D Yeghiazaryan L Holtzman D Islam S Kumsa A Leblanc GJ Leonovich O Mamsa S Manzur-Ul-Alam M Myint Z Padayachee S Franke MF Hewison C
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2022 Mar 04; . doi: 10.1093/cid/ciac176. Epub 2022 03 04
adverse events combination therapy endTB linezolid

Growth and CD4 patterns of adolescents living with perinatally acquired HIV worldwide, a CIPHER cohort collaboration analysis.

Abstract

INTRODUCTION: Adolescents living with HIV are subject to multiple co-morbidities, including growth retardation and immunodeficiency.

Jesson J Crichton S Quartagno M Yotebieng M Abrams EJ Chokephaibulkit K Le Coeur S Aké-Assi MH Patel K Pinto J Paul M Vreeman R Davies MA Ben-Farhat J Van Dyke R Judd A Mofenson L Vicari M Seage G Bekker LG Essajee S Gibb D Penazzato M Collins IJ Wools-Kaloustian K Slogrove A Powis K Williams P Matshaba M Thahane L Nyasulu P Lukhele B Mwita L Kekitiinwa-Rukyalekere A Wanless S Goetghebuer T Thorne C Warszawski J Galli L van Rossum AMC Giaquinto C Marczynska M Marques L Prata F Ene L Okhonskaya L Navarro M Frick A Naver L Kahlert C Volokha A Chappell E Pape JW Rouzier V Marcelin A Succi R Sohn AH Kariminia A Edmonds A Lelo P Lyamuya R Ogalo EA Odhiambo FA Haas AD Bolton C Muhairwe J Tweya H Sylla M D'Almeida M Renner L Abzug MJ Oleske J Purswani M Teasdale C Nuwagaba-Biribonwoha H Goodall R Leroy V
Journal of the International AIDS Society 2022 Mar ; 25(3); e25871. doi: 10.1002/jia2.25871. Epub 2022 03 07
CD4 HIV adolescent cohort studies growth perinatally acquired